Variant forms of urate oxidase and use thereof

• US 9,926,537 B2
• Filed: 07/13/2017
• Issued: 03/27/2018
• Est. Priority Date: 04/11/2005
• Status: Active Grant

• Current Assignee: Horizon Therapeutics USA, Inc. (Amgen Inc.)
• Original Assignee: Horizon Pharma Rheumatology LLC (Amgen Inc.)
• Inventors: Hartman, Jacob, Mendelovitz, Simona
• Primary Examiner(s): Ha, Julie
• Application Number:
  US15/649,462
• Publication Number:
  US 20170321193A1
• Time in Patent Office: 257 Days
• Field of Search: 43525233, 4353201, 435191, 435 89, 435188, 4352523, 4352542, 435325, 435348, 435 9, 435 911, 536 232, 536 231, 424 943, 424 944
• CPC Class Codes: A61K 38/44 Oxidoreductases (1)
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 19/06 Antigout agents, e.g. antihyperuricemic or uricosuric agents
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 9/0046 with oxygen as acceptor (1.7.3)
• CPC Class Codes: C12N 9/0048 Uricase (1.7.3.3)
• CPC Class Codes: C12Y 107/03003 Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase

Abstract

Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.

Claims

1. A nucleic acid molecule comprising a polynucleotide sequence encoding a polypeptide, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:

8.

2. The nucleic acid molecule of claim 1, comprising the polynucleotide sequence of SEQ ID NO:

10.

3. The nucleic acid molecule of claim 1, wherein the polynucleotide sequence is operatively linked to an osmB promoter.

4. A nucleic acid vector comprising the nucleic acid molecule of claim 1.

5. A host cell comprising the nucleic acid vector of claim 4.

6. The host cell of claim 5, wherein the host cell is an Escherichia coli (E. coli).

7. An E. coli comprising a nucleic acid molecule comprising a polynucleotide sequence encoding a polypeptide, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:

8.

8. The E. coli of claim 7, comprising the polynucleotide sequence of SEQ ID NO:

10.

9. The E. coli of claim 7, wherein the polynucleotide sequence is operatively linked to an osmB promoter.

10. A method for producing a polypeptide comprising:

(i) culturing an E. coli comprising a nucleic acid molecule comprising a polynucleotide sequence encoding a polypeptide, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO;

8, under conditions such that the polynucleotide sequence is expressed by the host cell; and

(ii) isolating the expressed polypeptide.

11. The method of claim 10, comprising the polynucleotide sequence of SEQ ID NO:

10.

12. The method of claim 10, wherein the polynucleotide sequence is operatively linked to an osmB promoter.

13. The method of claim 10, further comprising conjugating the isolated polypeptide to polyethylene glycol (PEG).

14. The method of claim 13, wherein the PEG is monomethoxyPEG (mPEG).

15. The method of claim 14, wherein the mPEG has a molecular weight between 5 kDa and 20 kDa.

16. The method of claim 15, wherein the mPEG has a molecular weight of about 10 kDa.

17. The method of claim 16, wherein the mPEG is covalently attached to a lysine residue of the uricase.

18. The method of claim 16, comprising about 2-12 mPEG molecules per polypeptide.

19. A method for producing a conjugate comprising a polypeptide and PEG comprising:

(i) providing a polypeptide comprising the amino acid sequence of SEQ ID NO;

8; and

(ii) conjugating the polypeptide to polyethylene glycol (PEG).

20. The method of claim 19, wherein the PEG is monomethoxyPEG (mPEG).

21. The method of claim 20, wherein the mPEG has a molecular weight between 5 kDa and 20 kDa.

22. The method of claim 21, wherein the mPEG has a molecular weight of about 10 kDa.

23. The method of claim 22, wherein the mPEG is covalently attached to a lysine residue of the polypeptide.

24. The method of claim 23, wherein the conjugate comprises about 2-12 mPEG molecules per polypeptide.

25. The method of claim 24, wherein the conjugate is prepared with monomethoxy-poly(ethylene glycol)-nitrophenyl carbonate.